Pharmaceutical Executive January 6, 2025
In the race to bolster pipelines and drive growth, biopharma manufacturers are reexamining traditional practices and reimagining market research protocols.
Biopharma business development and licensing (BD&L) executives operate in a unique arena, enjoying a privileged view of future pipeline plans while shouldering the weight of high-stakes, high-visibility decisions. These leaders contend with compressed timelines, constant C-suite scrutiny, and the knowledge that even small misperceptions can compound into decisions with far-reaching implications — sometimes affecting the stock prices of both the buyer and the seller.
Despite the inherent challenges, BD&L executives are often energized by the importance of their roles, buoyed in part by their pride in knowing only a small number of biopharma executives will ever claim the experience. Navigating...
Today's Sponsors
Today's Sponsor